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Liver injury after the 
intravenous amiodarone 
administration in patient 
with impaired heart function
ABSTRACT
While many adverse effects have been associated with long-term oral amiodarone therapy, acute hepatotoxicity from intra-
venous administration of amiodarone is a rare side effect. This case report focuses on a 78-year-old critically ill female, who 
underwent several urgent surgical procedures and had elevated liver aminotransferases concentrations after the intraveno-
us administration of amiodarone for the treatment of atrial fibrillation. Also, the patient developed heart failure with reduced 
left ventricular systolic function. Immediately after the discontinuation of amiodarone therapy, liver aminotransferases levels 
began to decline. Our case suggests that regular monitoring of hepatic function is required in patients receiving intravenous 
amiodarone, especially in the setting of impaired heart function and possible liver hypoperfusion. 
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Introduction
Amiodarone is a class III antiarrhytmic 
drug that prolongs intranodal conduc-
tion and refractoriness of the atrio-
ventricular node. It is metabolised in 
the liver to N-desethylamiodarone, a 
metabolite primarily excreted in bile. 
(1) Amiodarone is used to treat ventri-
cular and supraventricular tachyarrhyt-
hmias and is thought of as one of the 
safest antiarrhythmic agents, in par-
ticular in patients with a low ejection 
fraction (EF) or clinical heart failure. 
(2) In patients with pre-existing left ven-
tricular dysfunction amiodarone may 
exert negative inotropic effects. (2) 
During long-term oral therapy, accu-
mulation of the drug in tissues may 
be responsible for thyroid dysfunction, 
corneal microdeposits, skin manife-
stations, gastrointestinal disturbances 
and pulmonary and hepatic toxicity. (3) 
The most prominent adverse effect of 
intravenous (i.v.) amiodarone therapy 
is hypotension which occurs in 26% 
of patients and is presumably caused 
by solvents used in the preparation. 
Hypotension appears more frequently 
in patients with EF less than 35%, cri-
tically ill patients and postcardiac sur-
gery patients. (2) Proarrhythmic effects 
may occur manifested as “torsades 
de pointes” or ventricular fibrillation. 
(4) An asymptomatic rise of liver ami-
notransferases occurs in about 25% 
of patients receiving oral amiodarone, 
whereas severe liver injury with poten-
tially fatal complications and cirrhosis 
occurs in less than 1% of patients. 
(5,6) Elevated bilirubin levels may be 
the first sign of toxic effects. Bilirubin 
levels may stay elevated after discon-
tinuation of the drug because of its 
long half-life. (7) Though less com-
mon, cases of acute hepatotoxicity 
after i.v. amiodarone have also been 
reported. In two patients fatal hepa-
tocellular necrosis has been reported. 
(4) Abnormal liver function tests occur 
in 1 to 5% of patients receiving i.v. 
amiodarone. (4,8) The dilutent polysor-
bate 80 present in the i.v. form of the 
drug is presumably responsible for the 
hepatotoxic effects. (9) Polysorbate 
80 has been associated with E-ferol 
syndrome described in infants after the 
i.v. usage of vitamin E. This syndrome 
shares similar clinical features with the 
acute amiodarone hepatotoxicity.9
Case report
A 78-year-old female was admitted 
to the intensive care unit (ICU) prior 
to an urgent surgical procedure due 
to rectal prolapse. Her past medical 
history included chronic obstructive 
pulmonary disease and osteoporosis 
without known cardiovascular dise-
ases. Her home medications inclu-
ded theophylline and raloxifene. She 
has no history of alcohol abuse. Initial 
laboratory tests in the ICU were wit-
hin normal reference range, and liver 
aminotransferases levels were slightly 
elevated (table 1). At admittance she 
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presented atrial fibrillation (AF) with 
a rapid ventricular rate. After the i.v. 
dose of 300 mg of amiodarone and ini-
tial stabilization, a rectal excision with 
loop sigmoidostomy was performed. 
At the time she was hypotensive, and 
noradrenalin in a continuous infusion 
was administered until the following 
day. On the third postoperative day 
Hartmann’s operation was performed 
due to the prolapsed stoma. Also, she 
developed left brachial artery throm-
bosis which was treated by Fogarty 
thrombectomy. On the following day 
she became hypotensive again with 
a heart rate of 180/min. An echocar-
diogram of the heart showed reduced 
systolic function of the nondilated left 
ventricle with EF of 25-30%. A bolus 
dose of 300 mg of amiodarone was 
administered and a continuous infu-
sion was started. Synchronized elec-
trical cardioconversion was attempted 
unsuccessfully. Because of persistent 
hypotension and signs of heart failu-
re, noradrenalin and dobutamin were 
initiated (table 1). An amiodarone infu-
sion was continued for the next two 
days along with vasoactive therapy. 
On the third day after the start of the 
amiodarone infusion, elevated levels 
of liver enzymes were observed (table 
1). Amiodarone was suspected to be 
the cause of liver injury and infusion 
was discontinued. The total dose of 
administered amiodarone was 1842 
mg over a period of 55 hours. Liver 
transaminases were checked daily 
and a steady decline in their values 
was observed with a return to baseline 
after eight days (table 1). Eventually, 
the patient’s medical condition worse-
ned with a perforation of the transverse 
colon and she died from severe sepsis 
complications.
Discussion 
Liver injury after parenteral amiodaro-
ne therapy presents with acute elevati-
on of liver aminotransferases within 1-3 
days, which was noticed in our case 
as well. (10) Ischemic hepatitis, as the 
most common cause of elevated ami-
notransferases in hospitalized patients, 
shares many clinical and histological 
characteristics with amiodarone hepa-
totoxicity. (10) It is characterized by 
acute elevation of liver transaminases 
which return to baseline values within 
days following circulatory progress. 
It has been hypothesised that acute 
liver injury after the amiodarone admi-
nistration is more likely a result of liver 















HR/min BP HR control BP/HF control
1 57 53 41 170 9 140-180 ↓ amiodarone 300 mg noradrenaline
0-08 μg/kg/min
2 55 57 50 153 56 11 100-130 ↔ bisoprolol 2.5 mg stopped
4 47 43 54 171 70 10 90-150 ↔
bisoprolol 2.5 mg  
amiodarone 300 mg 
 + 5.1 μg/kg/min
+  SE cardioversion
5 67 78 60 7 120-180 ↓↓
























bisoprolol 2.5 mg  





8 645 625 101 416 93 33 90-120 ↔ bisoprolol 2.5 mg 
metildigoxin 0.2 mg 
stopped
9 335 253 67 219 66 38
80-120 ↑
bisoprolol 2.5 mg 
metildigoxin 0.1 mg 
10 214 137 78 167 66 43
11 147 69 127 72 45
14 67 40 215 104 48
15 41 25 67 34
18 26 27 62 68 59
24 110-160 ↓↓ Exitus letalis
ALT - alanine aminotransferase, AP - alkaline phosphatase, AST - aspartate aminotransferase, BIL - bilirubin, U/L - units per 
liter, BP - blood pressure, GGT -  gama glutamile transferase, HF - heart function, HR - heart rate, ICU – intensive care unit, 
LDH - lactate dehydrogenase, SE cardioconversion - synchronized electrical cardioconversion
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ischemia than drug toxicity, since most 
patients receiving amiodarone also 
have chronic cardiovascular illnesses. 
(10) Whether acute aminotransferases 
elevation in our patient was a result 
solely of amiodarone hepatotoxicity is 
arguable. Although acute elevation of 
liver aminotransferases was noticed 
after the initiation and a decline in their 
values was noticed in a 12-hour period 
after stopping the amiodarone infusi-
on, the patient was haemodynamically 
compromised. Her aminotransferases 
levels were moderately elevated befo-
re receiving amiodarone which may 
be attributable to ischemic hepatitis. 
Normalization of aminotransferases 
levels within days may have also been 
a result of circulatory improvement. 
A total dose of administered amioda-
rone in the period of 55 hours was in 
accordance with recommendations 
from the literature. (4) Nevertheless, for 
the patient who weighed 39 kg  it may 
have been excessive and contributed 
to liver injury.
Conclusion
Many critically ill patients receive i.v. 
amiodarone for the treatment of acute 
arrhythmias in the setting of impaired 
heart function. Intravenously administe-
red amiodarone may have direct toxic 
effects or may damage liver tissue in the 
presence of liver ischemia due to heart 
failure. Our case suggests that regular 
monitoring of liver function is necessary 
to prevent severe liver injury when ami-
odarone is administered parenteraly in 
patients with impaired heart function.
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